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ABSTRACT
The death of sympathetic neurons after nerve
growth factor (NGF) withdrawal requires de novo
gene expression. Dp5 was one of the first NGF
withdrawal-induced genes to be identified and it
encodes a proapoptotic BH3-only member of the
Bcl-2 family. To study how dp5 transcription is regu-
lated by NGF withdrawal we cloned the regulatory
regions of the rat dp5 gene and constructed a series
of dp5-luciferase reporter plasmids. In microinjec-
tion experiments with sympathetic neurons we
found that three regions of dp5 contribute to its
induction after NGF withdrawal: the promoter,
a conserved region in the single intron, and
sequences in the 3’ untranslated region of the dp5
mRNA. A construct containing all three regions is
efficiently activated by NGF withdrawal and, like
the endogenous dp5, its induction requires mixed-
lineage kinase (MLK) and c-Jun N-terminal kinase
(JNK) activity. JNKs phosphorylate the AP-1 tran-
scription factor c-Jun, and thereby increase its
activity. We identified a conserved ATF site in the
dp5 promoter that binds c-Jun and ATF2, which is
critical for dp5 promoter induction after NGF
withdrawal. These results suggest that part of the
mechanism by which the MLK-JNK-c-Jun pathway
promotes neuronal apoptosis is by activating the
transcription of the dp5 gene.
INTRODUCTION
Apoptosis occurs extensively during the normal develop-
ment of the mammalian nervous system, and is important
for establishing neuronal populations of the correct size
and for eliminating neurons that have made inappropriate
connections (1,2). Developing sympathetic neurons
depend on nerve growth factor, synthesized by their
target tissues, for survival. In the absence of nerve
growth factor (NGF), these cells die by apoptosis and
their death requires de novo gene expression (3).
Sympathetic neurons have been widely used for in vitro
studies of the molecular mechanisms of neuronal apopto-
sis and a considerable amount has been learned about
the signalling pathways that regulate the cell death
programme (4,5). Following NGF withdrawal, the
stress-responsive mixed-lineage kinase (MLK) and c-Jun
N-terminal kinase (JNK) protein kinase cascade is acti-
vated and JNKs phosphorylate the AP-1 transcription
factor c-Jun, which increases c-Jun activity and c-Jun
expression (6–10). The MLK-JNK-c-Jun pathway is
required for normal NGF withdrawal-induced death and
promotes the release of mitochondrial cytochrome c and
caspase activation (11–15).
The release of cytochrome c and other proapoptotic
proteins from mitochondria is regulated by the Bcl-2
protein family (16). In sympathetic neurons, the multi-
domain proapoptotic Bcl-2 family member Bax is essen-
tial for cytochrome c release and cell death after NGF
deprivation (17). In contrast, the antiapoptotic proteins
Bcl-2 and Bcl-xL, which can form heterodimers with
Bax, inhibit cytochrome c release and protect against
NGF withdrawal-induced death (14,18–20). Finally,
several proapoptotic BH3-only Bcl-2 family members
are expressed in sympathetic neurons and three of these
are regulated by NGF withdrawal: the dp5, bim and
puma mRNAs and proteins increase in level after
NGF deprivation, in all cases before the cell death com-
mitment point (14,21–24). These BH3-only proteins
may promote sympathetic neuron apoptosis by binding
to the antiapoptotic members of the Bcl-2 family,
which would then be unable to interact with Bax,
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Bax (25).
The BH3-only proteins that increase in level after NGF
withdrawal are downstream targets of the MLK-JNK-
c-Jun pathway. Expression of a c-Jun dominant negative
mutant (Jun169) or the JunAA knock-in mutation in
mice, which eliminates the two major JNK phosphoryla-
tion sites in c-Jun, reduce the increase in bim RNA and
protein levels after NGF withdrawal (14,24). In addition,
the MLK inhibitor CEP-1347, which prevents JNK acti-
vation, also reduces the increase in bim and dp5 mRNA
levels after NGF deprivation (22,23). To understand in
general how JNKs and AP-1 transcription factors pro-
mote neuronal apoptosis it is important to determine the
molecular mechanisms by which these proteins regulate
Bim and Dp5 expression and NGF-dependent sympa-
thetic neurons have been a useful model for these studies
(26,27). Here, we use a dp5 reporter gene assay, expression
vectors for JNK and AP-1 inhibitor proteins, speciﬁc
chemical inhibitors, and site-directed mutagenesis to
investigate how NGF withdrawal activates dp5 transcrip-
tion in sympathetic neurons. We show that an ATF-bind-
ing site in the dp5 promoter, closely related in sequence to
the jun1 and jun2 TRE elements in the c-jun promoter, can
bind c-Jun and ATF2 in vitro and in chromatin, and is
critical for dp5 promoter activity in sympathetic neurons
and for promoter induction following NGF withdrawal.
MATERIALS AND METHODS
5’ RACE and cloningof thedp5 promoter
50 rapid ampliﬁcation of cDNA ends (RACE) was per-
formed on rat brain mRNA using the Marathon
TM
cDNA ampliﬁcation kit (Clontech Laboratories Inc.)
with the dp5-speciﬁc primer 50-CTGCAGCCGCAGCGC
GGTCACC-30. To isolate the dp5 promoter, the 50 RACE
product was used as a probe to screen the rat P1 artiﬁcal
chromosome (PAC) library RPCI31 (generated by P.Y.
Woon and P. de Jong, UK Human Genome Mapping
Project Resource Centre, Cambridge, UK). A 4-kb frag-
ment from upstream of exon 1 was cloned and the remain-
ing promoter sequence between the start codon and
upstream 4kb fragment was generated by PCR. These
sequences were ligated at an EcoRI restriction site to gen-
erate a 4.5kb fragment in pGEM-T Easy (Promega UK
Ltd, Southampton, UK).
Plasmid constructs
The dp5 reporter construct dp5-LUC was generated by
subcloning a 1017bp fragment containing the dp5 pro-
moter sequence from  980 to +37, relative to the tran-
scriptional start site, into pGL3-basic (Promega UK Ltd.),
upstream of the luciferase gene. To obtain a reporter con-
struct also containing part of the dp5 intron (dp5-LUC+I
400), a 395bp region of the intron that is highly conserved
was subcloned into dp5-LUC downstream of the SV40
polyadenylation termination sequence. The construct
dp5-LUC+30 UTR was made by subcloning three frag-
ments (a 645bp fragment containing the dp5 stop codon,
a 2.36kb fragment and a 2.02kb fragment) that spanned
the entire dp5 30 UTR into dp5-LUC downstream of
the luciferase gene. dp5-LUC+ALL was generated by
subcloning the 395bp intron fragment into dp5-
LUC+30 UTR. For all constructs, fragment orientation
and positioning was conﬁrmed by restriction enzyme ana-
lysis and DNA sequencing.
Point mutations within the ATF-binding site in the
dp5 promoter were introduced into dp5-LUC+ALL
using the QuikChange
TM II XL site-directed mutagenesis
kit (Stratagene Europe, Amsterdam, The Netherlands)
and the oligonucleotides 50-CCCGGGCCGGATAACG
TCTCCCCCTCCCCGCG-30 and 50-CGCGGGGAGGG
GGAGACGTTATCCGGCCCGGG-30 containing four
point mutations. Incorporation of the correct mutations
was conﬁrmed by DNA sequencing.
The expression vectors for the JIP-1 JNK-binding
domain (JBD) and c-Jun (ala) are described in (12)
and (28).
Cellculture
Sympathetic neurons were prepared from the superior cer-
vical ganglia (SCG) of 1-day-old Sprague Dawley rats
(supplied by the Biological Services Unit, University
College London). Neurons were isolated and cultured as
described previously (29), in DMEM (Sigma-Aldrich,
Poole, UK) containing 10% foetal calf serum, 2mM glu-
tamine (Invitrogen Ltd, Paisley, UK) and penicillin-strep-
tomycin (SCG medium). Unless stated otherwise, SCG
medium was supplemented immediately prior to use with
2.5S NGF (Cedarlane Laboratories Ltd., Hornby,
Ontario) at 50ng/ml and the antimitotic agents ﬂuoro-
deoxyuridine and uridine (both from Sigma-Aldrich)
each at 20mM. Sympathetic neurons were plated on
13mm diameter glass coverslips coated with poly-L-
lysine and laminin placed in 3.5cm dishes. Cells were
maintained in 2ml of medium at 378C in 10% CO2 for
5–7 days before being used for experiments. In NGF with-
drawal experiments, the growth medium was removed and
the cells were gently rinsed twice with SCG medium lack-
ing NGF and antimitotic agents. The neurons were then
refed with fresh medium containing NGF or a neutralising
anti-NGF antibody (Chemicon Europe Ltd, Chandlers
Ford, UK) at 100ng/ml. The MLK3 inhibitor CEP-
11004 (provided by Cephalon, Inc., West Chester, PA)
was dissolved in DMSO and used at a ﬁnal concentration
of 400nM.
The PC6-3 subline of the PC12 cell line (30) was cul-
tured in RPMI 1640 medium (Invitrogen Ltd.) supplemen-
ted with 10% horse serum, 5% FCS, 2mM glutamine and
penicillin/streptomycin. Cells were grown on collagen-
coated tissue culture dishes at 378Ci n5 %C O 2 and pas-
saged once a week. For diﬀerentiation, cells were plated at
a density of 1 10
6 cells per 9cm dish and maintained for
7 days in RPMI 1640 medium containing 2% horse serum,
1% FCS, penicillin/streptomycin and NGF (Promega UK
Ltd.) at 100ng/ml. In NGF withdrawal experiments, the
neuronally diﬀerentiated PC6-3 cells were rinsed twice
with diﬀerentiation medium lacking NGF and then refed
with medium containing NGF or anti-NGF antibody,
as required.
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Sympathetic neurons were microinjected as described pre-
viously (14). The diﬀerent reporter constructs and expres-
sion vectors were injected at the concentrations indicated
(see Results). The injection mix contained the DNA to
be tested in 0.5  PBS (–Ca
2+, –Mg
2+) (Sigma-Aldrich)
plus 5–10ng/ml of the Renilla luciferase construct pRL-TK
(Promega) to control for variations in the volume of DNA
or number of cells injected per coverslip. The DNA was
injected directly into the nucleus and at least 120 neurons
were injected for each condition tested. Typically 50–80%
of the neurons survived injection.
At 16–24h after injection, the neurons were harvested
and luciferase activity was determined using the Dual-
Luciferase reporter assay system (Promega). Neurons
were rinsed oﬀ the coverslips in ice-cold PBS and were
collected by centrifugation before being lysed in 25mlo f
passive lysis buﬀer. The luciferase assay was then per-
formed using a Lumat LB 9507 luminometer following
the protocol provided with the assay system. The output
for ﬁreﬂy luciferase was normalized to the Renilla lucifer-
ase output (ﬁreﬂy luciferase output divided by Renilla luci-
ferase output). The relative induction of each construct
was then calculated (for example, normalized luciferase
activity in the absence of NGF divided by normalized
luciferase activity in the presence of NGF). Each experi-
ment was performed at least three times using diﬀerent
neuron preparations and the standard error of the mean
was calculated.
For antibody co-injection experiments, the c-Jun
(H-79) X and ATF2 (C-19) X rabbit polyclonal antibodies
(Santa Cruz Biotechnology Inc.) were diluted in PBS
( Ca
2+,  Mg
2+) and centrifuged in Microcon YM-3
centrifugal ﬁlters (Millipore Corporation, Bedford, MA)
to remove sodium azide. The ﬁnal antibody concentration
was adjusted to 2mg/ml. Puriﬁed rabbit immunoglobulin in
PBS (Jackson ImmunoResearch Laboratories, Inc.) was
used as a control. Neurons were microinjected with dp5-
LUC+ALL or pLuc-MCS or pCRE-Luc (Stratagene) all
at 20ng/ml, pRL-TK (10ng/ml) and antibody (1mg/ml).
After injection, in the case of dp5-LUC+ALL, the cells
were rinsed twice with SCG medium and refed with
medium containing NGF or anti-NGF antibody. For
pLuc-MCS and pCRE-Luc the injected cells were refed
with+NGF medium containing 500mM CPTcAMP
(Sigma-Aldrich). Twenty hours later, the cells were har-
vested and a dual luciferase assay performed.
RT–PCR
RNA was isolated from sympathetic neurons using
an RNeasy kit (QIAGEN Ltd.). Total RNA was eluted
in 30ml and, after treatment with ampliﬁcation grade
DNase I (Invitrogen Ltd) to remove any contaminating
DNA, 10ml of the puriﬁed RNA was reverse transcribed
using Superscript II reverse transcriptase (Invitrogen Ltd).
Fifty microliter PCR reactions were prepared using 1–4ml
of cDNA, 0.2mM dNTPs, 0.1mg of oligonucleotide pri-
mers and 0.05U/ml of REDTaq DNA polymerase in 1 
RedTaq PCR reaction buﬀer (Sigma-Aldrich). Cycling
parameters were 948C for 30s, 588C for 20s and 728C
for 60s and PCR cycles were performed a suﬃcient
number of times for a product to be detected for each
sample in a set, typically 30–38 cycles. The ampliﬁed pro-
ducts were resolved on 2.5% agarose gels containing ethi-
dium bromide at 0.5mg/ml. Images were captured using
a UVIdoc gel documentation system (UVItec Ltd,
Cambridge, UK) and quantiﬁed using ImageMaster
TotalLab imaging software (GE Healthcare UK Ltd,
Chalfont St. Giles, UK). Experiments were performed
four times and the average of three PCR reactions and
SEM were calculated for each cDNA sample. The follow-
ing primers were used:
dp5,5 0-AGACCCAGCCCGGACCGAGCAA-30 and
50-ATAGCACTGAGGTGGCTATC-30;
neuroﬁlament (nf-m), 50-ACGCTGGACTCGCTGGGCA
A-30 and 50-GCGAGCGCGCTGCGCTTGTA-30.
In vitro transcription andtranslation
ATF2, c-Fos, c-Jun, c-Jun169 and 169m0 were pro-
duced in vitro using the TNT T7 or T3 Coupled
Reticulocyte Lysate system (Promega). All plasmids used
contained the b-globin RNA leader sequence, which
increases translation eﬃciency. The plasmid pBAT
ATF2 (31) was used with the T3 coupled system as a tem-
plate for the synthesis of ATF2. All other proteins were
translated using the T7 coupled system. T7c-Fos was pro-
vided by Curt Pfarr and Moshe Yaniv (Institut Pasteur,
Paris). The plasmid pCDc-Jun and pCDFLAG169, the
expression vector for a c-Jun dominant negative mutant,
are described in (7). 169m0 protein was made using the
plasmid pCDFLAG169m0, in which the m0 leucine
zipper mutation (31) had been transferred into the c-Jun
sequences in pCDFLAG169 by subcloning. After
coupled transcription/translation at 308C for 60min in a
volume of 50ml, an equal volume of 2x dialysis buﬀer
(40mM Hepes pH 7.9, 50mM KCl, 2mM MgCl2,1m M
EDTA, 1mM DTT, 1mM PMSF, 20% glycerol) was
added to each translation. The translated proteins were
divided into aliquots, frozen on dry ice, and stored at
 808C.
In some experiments, the in vitro translated proteins
were labelled with
35S-methionine and run on a 12%
SDS polyacrylamide gel. The gel was ﬁxed, treated with
Amplify
TM solution (GE Healthcare UK Ltd.) and dried
using a BioRad gel dryer (model 583) before being
exposed to Hyperﬁlm
TM X-ray ﬁlm (GE Healthcare
UK Ltd).
Electrophoretic mobility shiftassays
Double-stranded oligonucleotides were labelled with
[a-
32P]dCTP (3000Ci/mmol; PerkinElmer) using Klenow
polymerase (Roche Diagnostics Ltd, Lewes, UK) to ﬁll in
50 overhangs. The following pairs of oligonucleotides were
used (binding sites are underlined): collagenase TRE, 50-C
TAGAGCATGAGTCAGACAC-30 and 50-CTAGGTGT
CTGACTCATGCT-30; jun2 TRE, 50-CTAGAGCATT
ACCTCATCCC-30 and 50-GTACGGGATGAGGTAA
TGCT-30; dp5 ATF, 50-CTAGGCCGGATGATGTAAC
CCCCT-30 and 50-CTAGAGGGGGTTACATCATCCG
3046 Nucleic Acids Research, 2009, Vol. 37,No. 9GC-30; dp5 ATF mutant, 50-CTAGGCCGGATAACGTC
TCCCCCT-30 and 50-CTAGAGGGGGAGACGTTATC
CGGC-30.
Binding reactions were prepared with 40mM KCl,
20mM Hepes pH 7.9, 5mM MgCl2, 1mM EGTA,
0.5mM DTT, 10% glycerol, 0.5mg/ml BSA, 1mg poly(dI-
dC) and 4mlo fin vitro translated protein/unprogrammed
rabbit reticulocyte lysate to a ﬁnal volume of 19ml. The
reaction was prepared without the radiolabelled oligonu-
cleotide, and incubated at room temperature for 15min.
One microlitre containing 0.4ng of
32P-labelled probe
was then added before a further 15min incubation at
room temperature. The binding reactions were loaded
onto a 5% polyacrylamide/0.25  TBE native protein gel.
Following electrophoresis at 180V for  2h at room tem-
perature, the gel was ﬁxed for 15min in 10% acetic acid,
10%methanolanddriedat808Cundervacuum.Thebands
were visualised by exposing the dried gel to Kodak MXB
X-ray ﬁlm (Kodak Ltd, Hemel Hempstead, UK) or a
phosphorimager screen overnight. The exposed phosphor-
imager screen was scanned using a Typhoon
TM 8600 phos-
phorimager and the image analysed using ImageQuant
software and saved as a TIFF ﬁle. Exposed X-ray ﬁlms
were scanned using an Epson photo scanner (model
4990) and the resulting images were saved as TIFF ﬁles.
Sympathetic neuron whole-cell extracts for EMSA
experiments were prepared as follows. The SCG neurons
isolated from 30 1-day-old rats were plated in four 3.5cm
dishes coated with poly-L-lysine and laminin. After 7 days
in vitro, the medium was removed, the cells were rinsed
twice with SCG medium, and two dishes were refed with
medium containing NGF and two with medium contain-
ing anti-NGF antibody. Sixteen hours later, the dishes
were placed on ice and the medium was removed. The
neurons were then rinsed oﬀ using 1ml of ice-cold PBS
per dish and transferred to 1.5ml microfuge tubes on ice.
The cells were pelleted by centrifugation for 5min at 48C
and the cells from each pair of dishes were pooled and
resuspended in 1ml of ice-cold PBS. The cells were spun
again for 5min at 48C and then suspended in 30mlo f
whole cell extract buﬀer (0.1% NP-40, 250mM KCl,
50mM Hepes pH 7.9, 10% glycerol, 0.2mM EDTA,
0.2mM EGTA, containing the following inhibitors
added just before use, 4mM NaF, 4mM Na3VO4,1m M
DTT, 0.5mM PMSF, 2% v/v Sigma mammalian protease
inhibitor cocktail). The lysates were incubated on ice for
30min and were gently pipetted up and down from time to
time. Cell debris was removed by centrifugation for 30min
at 16000 g in a microfuge at 48C, and the supernatants
were frozen in aliquots on dry ice and stored at  808C.
Protein concentration was determined using the Bio-Rad
protein assay.
EMSA experiments with sympathetic neuron extracts
were carried out as described above, except that the
volume of the binding reaction was 25ml and 4mlo f
whole cell extract buﬀer was included. From 4 to 8mgo f
whole cell extract was used per binding reaction and for
supershift assays 2–4ml of antibody was added. The anti-
bodies were c-Jun (H-79) X, ATF2 (C-19) X, phospho-c-
Jun (KM-1) X (all from Santa Cruz Biotechnology, Inc.),
phospho-ATF2 (Thr71) (Cell Signaling Technology) and,
as a control, Bim AB17003 (Chemicon). Binding reactions
were for 2h at 48C, after which 0.4ng of the
32P-labelled
double-stranded oligo was added. The samples were incu-
bated for 15min at room temperature, and then electro-
phoresed on a 5% polyacrylamide, 0.25  TBE gel.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described (32) with a number of
modiﬁcations. Most of the buﬀers used were from an
Upstate ChIP assay kit (Upstate Ltd, Dundee, UK).
PC6-3 cells were plated at a density of 1 10
6 cells per
9cm dish and diﬀerentiated for 7 days. After 7 days, the
cell density had increased to  4 10
6 cells per 9cm dish.
The diﬀerentiated cells were rinsed twice and cultured in
medium containing NGF or anti-NGF antibody for 16h.
Proteins and DNA were cross linked by adding 37%
formaldehyde to the culture medium to a ﬁnal concentra-
tion of 1% and incubating at room temperature for 3h.
Two hundred microlitre of aliquots of fragmented chro-
matin ( 8 10
6 nuclei) were used per ChiP, and the c-Jun
(H-79) X and ATF2 (C-19) X antibodies were diluted
1:1000 in ChIP dilution buﬀer in a volume of 2ml. The
phospho-c-Jun (serine 63) KM-1 X antibody was diluted
1:100. For preclearing and for recovery of the immune
complexes 50% protein A/G-agarose (without DNA,
Santa Cruz Biotechnology, Inc.) in ChIP dilution buﬀer
containing BSA (10mg/ml) was used.
After immunoprecipitation, washing and DNA puriﬁ-
cation, ChIP samples were analysed by PCR using Taq
DNA polymerase and CoralLoad PCR buﬀer (QIAGEN
Ltd.). To detect binding of c-Jun and ATF2 to the jun1
and jun2 TREs in the rat c-jun promoter the following
primer pair was used: 50-TGGAGAAAGAAGGGCCCA
ACTGTAG-30 and 50-GTGCAACTCTGAGTCCTTATC
CAGC-30.PCR conditions were: 5min at 948C followed by
30–35 cycles of 30s at 948C, 45s at 528C, 1min at 728C,
followed by 10min at 728C. For the dp5 ATF site the
following primers were used: 50-AAGTTACCTCTCGG
CTTTTTCTCC-30 and 50-CTGGACCCCAAGTTTCGC
TC-30. PCR conditions were the same as those used for
c-jun except that annealing was for 45s at 628C and
Q-Solution (Qiagen Ltd, Crawley, UK) was added to the
PCR reactions to facilitate ampliﬁcation of the GC-rich
dp5 promoter fragment. The PCR products were run on
non-denaturing 8% polyacrylamide/1  TBE gels and then
stained with SYBR Green 1 (Sigma-Aldrich). Images were
captured using an UVIdoc gel documentation system
(UVItec Ltd) and saved as TIFF ﬁles.
Adenovirusinfection
Recombinant adenoviruses that express the FLAG-
tagged c-Jun dominant negative mutant FLAG169
(AdvJun169) or Escherichia coli b-galactosidase
(AdvlacZ) under the control of the CMV promoter were
previously described (14).Puriﬁed adenovirus preparations
were titred by TCID50 assay using HEK 293A cells, and by
infecting sympathetic neurons and performing immunocy-
tochemistry with the FLAG-speciﬁc M2 monoclonal
antibody (Sigma-Aldrich) or a monoclonal antibody
against b-galactosidase (Promega) as described (14).
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ing on glass coverslips were transferred into the wells of
24-well plates with 1ml of SCG medium per well. At
5 days in vitro, the medium was replaced with 0.5ml of
medium containing recombinant adenovirus particles at
the lowest multiplicity of infection (MOI) that would
lead to the expression of the FLAG169 or b-galactosi-
dase protein in  50% of infected neurons (14). After over-
night infection at 378C, the virus-containing medium was
removed and replaced with 1ml of fresh SCG medium
containing NGF. After 24–36h, the cells were gently
rinsed twice with SCG medium lacking NGF and
antimitotic agents and then refed with 1ml of SCG
medium containing NGF or anti-NGF antibody,
as appropriate. After a further 16–24h, the cells were
harvested for protein analysis or RNA analysis, as
described in the immunoblotting and RT–PCR sections,
respectively.
Immunoblotting
Neurons were washed oﬀ the coverslips into microfuge
tubes using ice cold PBS. After centrifugation, the neurons
were lysed in sample buﬀer (2% SDS, 2mM b-mercap-
toethanol, 60mM Tris, pH 6.8, 0.01% bromophenol
blue) by incubating at 1008C for 15min. Proteins were
separated on 12% SDS polyacrylamide gels and trans-
ferred to Immobilon-P (Millipore) using the Bio-Rad
Mini-PROTEAN III transfer system. Protein detection
was performed as described previously (14) or following
protocols supplied with the primary antibodies. The fol-
lowing primary antibodies were used: the M2 anti-FLAG
epitope mouse monoclonal antibody (Sigma-Aldrich),
a mouse monoclonal anti-b-galactosidase antibody
(Promega), a rat monoclonal anti-a-tubulin antibody
(Serotec Ltd, Kidlington, UK), a mouse monoclonal
anti-c-Jun antibody (BD Transduction Laboratories), a
mouse monoclonal phospho-c-Jun (serine 63) antibody
(KM-1; Santa Cruz Biotechnology, Inc.), a rabbit poly-
clonal phospho-c-Jun (serine 73) antibody (9164; Cell
Signalling Technology), a rabbit polyclonal anti-ATF2
antibody (C-19; Santa Cruz Biotechnology, Inc.), a
rabbit polyclonal phospho-ATF2 (threonine 71) antibody
(9221; Cell Signalling Technology), a rabbit polyclonal
ERK1/2 antibody (Cell Signalling Technology).
RESULTS
The dp5promoter, intron and3’ UTR contain sequences
that respond toNGF withdrawal insympathetic neurons
The rat dp5 gene contains two exons divided by an 18.9kb
intron, of which only a short region towards the 50 end is
conserved between the rat, mouse and human DNA
sequences. The Dp5 open reading frame (ORF) is located
in exon 1, which also contains part of the 30 UTR, the
remainder of which is contained within exon 2 (Figure 1a).
As a ﬁrst step in studying how dp5 expression is regu-
lated, we used the 50 RACE technique to map the major
dp5 RNA start site in rat brain mRNA. This is 37bp
upstream of the start of the Dp5 ORF and we designated
it as +1 (Figures 1a and 3). We then cloned diﬀerent
Figure 1. The dp5 promoter, intron and 30 UTR contain sequences that
respond to NGF withdrawal in sympathetic neurons. (a) Structure of
the rat dp5 gene. The rat dp5 gene consists of two exons and an 18.9kb
intron. The transcriptional start site mapped by 50 RACE is indicated
as +1 (see Figure 3 for DNA sequence). Exon 1 contains the Dp5
ORF (black box) as well as a small region of the 30 UTR, the remain-
der of which is in exon 2. A short region (<400bp long) towards the 50
end of the intron is conserved between the rat, mouse and human dp5
genes (grey box). (b) dp5 reporter gene structure and induction levels
in sympathetic neurons following NGF deprivation. The construct dp5-
LUC contains the dp5 promoter sequence from –980 to +37 cloned
upstream of the ﬁreﬂy luciferase gene (Luc) and the SV40 poly-A
termination signal (striped box). In addition to these sequences, other
constructs contained either  400bp from the conserved region of the
dp5 intron inserted downstream of the poly-A termination signal (dp5-
LUC+I 400), the dp5 30 UTR inserted downstream of luciferase
(dp5-LUC+30 UTR), or both the intron fragment and 30 UTR
inserted as above (dp5-LUC+ALL). The induction factor for each
reporter construct in sympathetic neurons following NGF withdrawal
is shown. (c) Relative luciferase activity of dp5 reporter constructs in
sympathetic neurons maintained in the presence and absence of NGF.
Sympathetic neurons were microinjected with dp5-LUC (5ng/ml), dp5-
LUC+I 400 (5ng/ml), dp5-LUC+30 UTR (15ng/ml) or dp5-
LUC+ALL (10ng/ml) together with pRL-TK (5ng/ml). Following
microinjection, cells were rinsed twice with medium lacking NGF and
were refed either with medium supplemented with NGF or medium
containing neutralising anti-NGF antibody. After 20–24h luciferase
activity was measured. Fireﬂy luciferase activity was normalized as out-
lined in the Materials and Methods and luciferase induction –NGF
(black bars) was calculated relative to +NGF (white bars), which
was set as 1. The mean of at least four independent experiments
 SEM is shown.
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luciferase reporter plasmids (Figure 1b). These contained
1kb of promoter sequence including the dp5 transcrip-
tional start site upstream of the ﬁreﬂy luciferase gene,
either alone or with the entire dp5 30 UTR and/or
 400bp of the conserved intron sequence (Figure 1b).
We microinjected the reporter constructs, together with
the control Renilla luciferase construct pRL-TK, into
the nuclei of sympathetic neurons cultured in vitro. After
injection, the cells were maintained for 16–24h in the pres-
ence of NGF or a neutralising anti-NGF antibody, after
which time relative luciferase activity was determined
by dual luciferase assay (33,34). In each case, the diﬀerent
dp5 reporter constructs were compared to the construct
containing only 1kb of the promoter sequence (dp5-
LUC). In microinjected neurons, this construct has a
much higher level of luciferase activity, i.e. promoter
activity, than the promoterless vector pGL3-Basic
(data not shown) and, after NGF withdrawal, it is
induced 2.03-fold ( 0.14) on average (Figure 1b). This
indicates that the 1kb dp5 promoter fragment contains
sequences that respond to NGF withdrawal. Following
NGF deprivation, both constructs containing the 1kb
dp5 promoter and either the conserved intron region or
the 30 UTR sequence showed higher levels of luciferase
activity than the construct with the promoter alone, with
induction factors of 3.61- and 3.23-fold, respectively
(Figure 1c). This suggests that these two regions also
contain elements that contribute to the increase in dp5
expression after NGF withdrawal. The construct dp5-
LUC+ALL, which contained 1kb of dp5 promoter
sequence, the conserved region of the intron, and the 30
UTR was induced the most after NGF deprivation,
4.81-fold (Figure 1c). Since dp5-LUC+ALL was eﬃ-
ciently activated by NGF withdrawal it was used as the
standard dp5 reporter construct in all subsequent
experiments.
Inhibition ofthe MLK-JNK pathwayreduces theincrease
in endogenousdp5 mRNA level and dp5reporter activity
after NGF deprivation
The MLK-JNK protein kinase cascade is activated by
NGF withdrawal in sympathetic neurons (9,10,11).
Mixed lineage kinases (MLKs) phosphorylate and activate
the JNK kinases MKK4 and MKK7, which in turn phos-
phorylate and activate JNKs (35). MLK activity can
be directly inhibited by the compound CEP-1347 (36).
Treatment of sympathetic neurons with CEP-1347
blocks NGF withdrawal-induced death (37) and reduces
dp5 mRNA induction following NGF deprivation by
 75% (22). In addition, it has been reported that CEP-
1347 reduces the increase in dp5 RNA level in cortical
neurons undergoing amyloid-beta-induced apoptosis (38).
To further study the role of the MLK-JNK pathway in
regulating dp5 expression we used CEP-11004, a MLK
inhibitor closely related to CEP-1347, which also inhibits
NGF withdrawal-induced death (39). We investigated the
eﬀect of CEP-11004 (at 400nM) on the level of c-Jun and
ATF2 and c-Jun and ATF2 phosphorylation in sympa-
thetic neurons cultured in the presence or absence of
NGF for 16 hours (Figure 2a). As previously described
(7), c-Jun protein levels and c-Jun N-terminal phosphor-
ylation increased after NGF withdrawal. The increased
phosphorylation was associated with a decrease in the
mobility of c-Jun in SDS PAGE. These changes were
reversed by CEP-11004. Similarly, phosphorylation of
c-Jun at serine 63 and serine 73 was signiﬁcantly increased
after NGF withdrawal and this increase was inhibited
by CEP-11004. In contrast, ATF2 protein levels did not
change after NGF withdrawal and phosphorylation of
ATF2 at threonine 71 was only marginally increased at
16h after the removal of NGF, as previously reported
(12). To determine whether CEP-11004 had the same
eﬀect on dp5 expression as CEP-1347, we treated sympa-
thetic neurons with CEP-11004 at 400nM in the presence
or absence of NGF for 16h and then isolated RNA
and measured dp5 mRNA levels by semi-quantitative
RT–PCR (Figure 2b). Following NGF deprivation, the
dp5 mRNA increased in level by 4.27-fold in untreated
control cells but this induction was reduced to 2.28-fold
in cells treated with 400nM CEP-11004 (Figure 2b and c).
We then investigated the eﬀect of CEP-11004 on the
activity of the dp5-LUC+ALL reporter construct in
microinjection experiments. The dp5 reporter construct
was induced 4.53-fold after NGF withdrawal and this
was reduced to a relative induction of 1.76-fold following
treatment with 400nM CEP-11004 (Figure 2d). This result
suggests that, like the endogenous dp5 gene, induction
of the dp5 reporter construct depends on MLK activity
in sympathetic neurons.
We also investigated the eﬀect of directly inhibiting
JNK activity by using the JBD of the scaﬀold protein
JNK interacting protein 1 (JIP-1), which binds to and
speciﬁcally inhibits JNKs but not other MAP kinases
(35). It has previously been shown that expression of
the JBD in sympathetic neurons inhibits JNK activity
and promotes cell survival following NGF withdrawal
(12,13). We microinjected an expression vector for the
JBD or the empty vector pcDNA3 into sympathetic neu-
rons together with dp5-LUC+ALL and luciferase activ-
ity was measured 20–24h after NGF withdrawal
(Figure 2e). Expression of the JBD strongly reduced the
induction of the dp5-LUC+ALL reporter construct after
NGF deprivation from 4.31-fold with pcDNA3 to
1.51-fold. This result indicates that JNK activity is
required for normal induction of the dp5 reporter con-
struct following NGF withdrawal.
Aconserved ATF site inthe dp5promoter binds c-Junand
ATF2and contributes todp5 basal promoter activity and
induction after NGF withdrawal
The AP-1 family of basic/leucine zipper transcription fac-
tors includes the Jun and ATF subfamilies. Both c-Jun
and activating transcription factor 2 (ATF2) are phos-
phorylated by JNKs after NGF deprivation in sympa-
thetic neurons (9,10,12), although, in the case of ATF2,
the increase in phosphorylation (at threonine 71) is more
transient (12). Importantly, microinjection of a neutralis-
ing c-Jun antibody, expression of a c-Jun dominant nega-
tive mutant or conditional knockout of the c-jun gene in
Nucleic Acids Research,2009, Vol.37, No. 9 3049sympathetic neurons in culture protects the cells from
NGF withdrawal-induced death (6,7,15). AP-1 family
members form homo- and heterodimers with each other,
which depending on the particular dimer, speciﬁcally bind
to the AP-1 site/TPA responsive element (TRE) (50-TGA
G/C TCA-30) or the ATF site/cAMP response element
(CRE) (50-TGA CG TCA-30) (35). The c-jun promoter
itself contains two ATF sites, the jun1 and jun2 TREs,
that bind heterodimers of c-Jun and ATF2 or ATF2
homodimers, and which are required for c-jun promoter
activation following NGF withdrawal in sympathetic
neurons (10).
Figure 2. Inhibition of the MLK-JNK pathway reduces the increase in endogenous dp5 mRNA level and the activation of a dp5 reporter construct
following NGF withdrawal. (a) CEP-11004 inhibits the increase in c-Jun protein level and c-Jun N-terminal phosphorylation that occurs after NGF
withdrawal. Sympathetic neurons were maintained in the presence or absence of NGF and were treated with either DMSO or CEP-11004 at 400nM
for 16h. The neurons were then harvested, lysed in SDS gel sample buﬀer and immunoblotting was performed with the antibodies indicated. The
level of ERK1/2 was used as a loading control. Three independent experiments were performed and representative immunoblots are shown. (b) CEP-
11004 reduces endogenous dp5 mRNA expression after NGF deprivation. Sympathetic neurons were maintained in the presence or absence of NGF
and were treated with either DMSO or CEP-11004 at 400nM for 16h. RNA was extracted and RT–PCR analysis performed using dp5 and
neuroﬁlament (nf-m) speciﬁc primers. Representative images of agarose gels are shown. (c) Relative levels of dp5 mRNA in sympathetic neurons
treated with CEP-11004 after NGF withdrawal. Following RT–PCR, band intensity was measured and the normalized dp5 level in each condition
was calculated relative to the level in cells treated with NGF and DMSO, which was set as 1. The mean of four independent experiments  SEM is
shown. At 400nM, CEP-11004 signiﬁcantly reduced the increase in dp5 mRNA level after NGF withdrawal ( NGF+CEP-11004 compared to
 NGF).  P<0.05, Student’s t-test. (d) CEP-11004 reduces induction of a dp5 reporter construct after NGF withdrawal in sympathetic neurons.
Sympathetic neurons were microinjected with dp5-LUC+ALL (10ng/ml) and pRL-TK (5ng/ml). Cells were maintained in the presence or absence of
NGF and were treated with either DMSO or 400nM CEP-11004 for 16h. Normalized luciferase activity was calculated relative to the level +NGF
treated with DMSO, which was set as 1. The mean of three independent experiments  SEM is shown. At 400nM, CEP-11004 signiﬁcantly reduced
the increase in the level of luciferase activity for dp5-LUC+ALL after NGF withdrawal ( NGF+CEP-11004 compared to  NGF).
#P<0.02,
Student’s t-test. (e) Expression of the JIP-1 JBD reduces induction of a dp5 reporter construct after NGF withdrawal. Sympathetic neurons were
microinjected with dp5-LUC+ALL (20ng/ml), pRL-TK (10ng/ml), and pcDNA3.1 or pCD JIP-1 JBD (100ng/ml). Cells were maintained +NGF or
–NGF for 20h and then luciferase activity was measured. Luciferase activity was calculated relative to the level +NGF injected with pcDNA3.1,
which was set as 1. The mean of six independent experiments  SEM is shown.
3050 Nucleic Acids Research, 2009, Vol. 37,No. 9To identify conserved, potential transcription factor
binding sites in the dp5 promoter, we aligned the DNA
sequence of the rat dp5 promoter from  115 to +24, in
relation to the transcriptional start site, with the corre-
sponding regions of the mouse, human and cow dp5
genes (Figure 3). Interestingly, we identiﬁed a potential
ATF-binding site (50-TGA TG TAA-30) at positions  96
to  89 in the rat dp5 promoter, which was conserved
between the rat, mouse, human and cow sequences
(Figure 3). Closer analysis of this site indicated that
it only diﬀers from the ATF/CRE consensus site by
2 bases and it is only 1 base diﬀerent from the jun2
TRE site in the c-jun promoter (Figure 4a).
We tested the ability of representative AP-1 family
members to bind to the dp5 ATF site in vitro in an
electrophoretic mobility shift assay (EMSA). We trans-
lated c-Fos, c-Jun and ATF2 in vitro (Figure 4b). As a
control, we tested the binding of these AP-1 proteins to
two well characterized binding sites, the collagenase TRE
(a consensus AP-1 site) and the jun2 TRE (an ATF site)
(Figure 4c). It has been reported that c-Jun homodimers
have a very low aﬃnity for both of these sites whereas
c-Jun/c-Fos heterodimers bind with high aﬃnity to the
collagenase TRE, and c-Jun/ATF2 heterodimers bind
with high aﬃnity to the jun2 TRE (31). In agreement
with these results, we observed a c-Jun/c-Fos/DNA com-
plex, but no binding of c-Jun or c-Fos alone, with the
collagenase TRE (lanes 1–4, Figure 4c), and a c-Jun/
ATF2/DNA complex, but no binding of c-Jun alone,
with the jun 2 TRE (lanes 5–8, Figure 4c). We then
tested the binding of the AP-1 proteins to the dp5 ATF
site (lanes 9–14, Figure 4c). Neither c-Jun nor c-Fos alone
bound to the dp5 sequence but c-Jun/c-Fos heterodimers
bound with a low aﬃnity (compare lane 11 with lane 3).
In contrast, c-Jun/ATF2 heterodimers and ATF2 homo-
dimers bound the dp5 site with an aﬃnity similar to the
aﬃnity of c-Jun/ATF2 for the jun2 TRE (compare lanes
12 and 13 with lane 7, Figure 4c). Mutation of the dp5
ATF site by the introduction of four base changes
(Figure 4a) abolished the binding of all of the AP1 pro-
teins (Figure 4d, lanes 8–14).
To investigate whether c-Jun and ATF2 in sympathetic
neuron extracts can bind to the dp5 ATF site we prepared
extracts from neurons that had been cultured in the pres-
ence or absence of NGF for 16h and performed an EMSA
experiment (Figure 5a). Extracts from neurons maintained
in the presence of NGF contained proteins that bound to
the dp5 ATF site (lane 2) and this binding (marked AP-1)
was abolished by point mutations in the ATF site (lanes 5
and 6). After NGF withdrawal, a similar amount of spe-
ciﬁc AP-1-binding activity was observed but the pattern
of bands was slightly diﬀerent (compare lanes 2 and 3).
To determine whether the speciﬁc protein complexes
contained c-Jun and ATF2 we added antibodies speciﬁc
for c-Jun or ATF2 or a Bim antibody, as a negative con-
trol, to the binding reactions. The Bim antibody did
not alter the binding pattern observed with the –NGF
extract (compare lanes 7 and 8) whereas the c-Jun anti-
body supershifted some of the AP-1 complexes (lane 9).
Phosphorimaging and quantitation revealed that the c-Jun
antibody supershifted 45% of the AP-1/dp5 complexes.
Addition of the ATF2 antibody did not cause a clear
supershift but did displace 42% of the AP-1/dp5 com-
plexes (compare lanes 10 and 7) and addition of both
the c-Jun and ATF2 antibodies together supershifted
71% of the speciﬁc protein complexes bound to the dp5
ATF site (compare lanes 11 and 7). We also performed an
EMSA experiment in which we tested the eﬀect of
Figure 3. Alignment of the promoter sequences for the rat, mouse, human and cow dp5 genes. Shaded regions indicate a conserved ATF site, a GC
box, an E box and a TATA box. Asterisks represent bases conserved in all four species. Overall, 80% of the nucleotides are conserved. The
transcriptional start site of the rat dp5 gene determined by 50 RACE is indicated as +1, together with the direction of transcription.
Nucleic Acids Research,2009, Vol.37, No. 9 3051phospho-c-Jun (serine 63) and phospho-ATF2 (threonine
71) antibodies (Figure 5b). With the –NGF extract the
phospho-c-Jun antibody supershifted the majority of the
AP-1 proteins bound to the dp5 ATF site (compare lane 15
to lanes 14 and 13). We conﬁrmed that this was a super-
shift by measuring the distribution of peaks in a vertical
line through the –NGF lanes in a phosphorimage of the
gel shown in Figure 5b. The AP-1 proteins were clearly
displaced towards the top of the gel in lane 15 compared
to lanes 14 and 13. In contrast, the phospho-ATF2 anti-
body only supershifted a small fraction of the dp5/AP-1
complex (compare lane 16 to lanes 14 and 13). These
results demonstrate that after NGF withdrawal the
c-Jun in sympathetic neuron extracts that binds to the
dp5 ATF site in vitro is phosphorylated at serine 63.
In the case of ATF2, a smaller fraction of the AP-1 com-
plex bound to the dp5 ATF site is phosphorylated
at threonine 71. We then compared the amount of
phospho-c-Jun supershifted in DNA-binding assays per-
formed with +NGF and –NGF extracts (Figure 5c).
Phosphorimaging and quantitation of the supershifted
complex in lanes 19 and 20 revealed that the amount of
c-Jun phosphorylated at serine 63 was 2-fold greater at
16h after NGF withdrawal.
To conﬁrm that c-Jun and ATF2 can bind to the region
of the dp5 promoter that contains the ATF site in living
cells, we performed ChIP assays using the Bim, c-Jun and
ATF2 antibodies. Since large numbers of cells are required
Figure 4. The dp5 promoter contains an ATF site that binds AP-1 proteins in vitro.( a) Sequences of ATF sites. The ATF consensus sequence is
shown together with the jun2 TRE sequence, the dp5 ATF site and a mutant dp5 ATF site. (b) In vitro translated proteins used for EMSA
experiments. ATF2, c-Fos, c-Jun, c-Jun169 and 169m0 were transcribed and translated in a rabbit reticulocyte lysate. Unprogrammed lysate
(RRL) was used as a negative control. The in vitro translated proteins were labelled with
35S-methionine and separated on a 12% SDS polyacry-
lamide gel. The size of molecular weight markers run on the same gel is shown. (c) ATF2 homodimers, c-Jun/ATF2 and c-Jun/c-Fos can bind to the
dp5 ATF site.
32P-labelled, double-stranded oligonucleotides containing either the collagenase TRE, the jun2 TRE, or the dp5 ATF site were
incubated with in vitro translated c-Jun, c-Fos, ATF2, or unprogrammed lysate (RRL), as indicated, and separated on a 5% polyacrylamide,
0.25  TBE gel. Several experiments were performed and a representative result is shown. Free probe, a non-speciﬁc complex (NS) and the AP-1
complexes are indicated. (d) Point mutations in the dp5 ATF site abolish the binding of AP-1 proteins in vitro. Oligonucleotides containing either the
wild type dp5 ATF site or a mutant site, in which four nucleotides have been changed (a) were used for EMSA experiments with in vitro translated
c-Jun, c-Fos, ATF2 or unprogrammed lysate (RRL), as indicated. Several experiments were performed and a representative result is shown.
3052 Nucleic Acids Research, 2009, Vol. 37,No. 9for conventional ChIP assays we used neuronally diﬀer-
entiated PC12 cells that had been cultured in the presence
or absence of NGF for 16h, rather than sympathetic neu-
rons. The binding of c-Jun or ATF2 to the c-jun and dp5
promoters was studied by PCR using primers that ﬂank
the jun1 and jun2 TREs (a positive control) or the dp5
ATF site, respectively (Figure 6a). The control antibody
(Bim) did not immunoprecipitate either the c-jun or dp5
promoter (lanes 3 and 4), whereas both the c-Jun and
ATF2 antibodies precipitated the region of the c-jun pro-
moter that contains the jun1 and jun2 TREs and the dp5
promoter region that contains the ATF site (lanes 5–8).
These results indicate that c-Jun and ATF2 can bind to the
dp5 ATF site in living cells. In the case of both c-jun and
dp5 the amount of c-Jun or ATF2 bound to the promoter
had not increased signiﬁcantly at 16h after NGF
withdrawal. These results are in agreement with previous
studies that showed that the jun1 and jun2 TREs in the
c-jun promoter are already bound by c-Jun and
ATF2-containing complexes in a variety of unstimulated
cells in culture and that the protein-DNA contacts are
unchanged during gene activation by TPA and UV (40).
Using an antibody speciﬁc for c-Jun phosphorylated
at serine 63 we also investigated whether the amount
of phospho-c-Jun associated with the c-jun and dp5 pro-
moters increased after NGF withdrawal (Figure 6b). We
found that the c-Jun bound to the c-jun promoter was
phosphorylated at serine 63 and that this increased in
level after NGF withdrawal (lanes 14 and 15). Similarly,
we also observed that there was increase in the amount of
phospho-c-Jun associated with the dp5 promoter at 16h
after NGF deprivation. In the case of both promoters, we
found that phosphorylation of ATF2 at threonine 71 had
not increased at 16h after NGF withdrawal (data not
shown), consistent with the results of the immunoblotting
experiments with sympathetic neuron extracts (Figure 2a).
We then investigated the eﬀect of introducing the four
point mutations shown to abolish AP-1 binding into the
construct dp5-LUC+ALL. The wild-type and mutant
constructs were microinjected into sympathetic neurons
and luciferase activity was measured after 20–24h in the
presence or absence of NGF (Figure 7). The mutations in
the ATF site in the dp5 promoter completely obliterated
its induction after NGF withdrawal by (i) decreasing the
basal activity of the construct by 86% (Figure 7a), and
(ii) by reducing the induction factor after NGF with-
drawal from 7.08- to 3.05-fold (Figure 7b). This demon-
strates that abolishing the binding of c-Jun and ATF2
Figure 5. c-Jun and ATF2 in sympathetic neuron extracts bind to the dp5 ATF site in vitro. Sympathetic neurons were cultured for 7 days and then
refed with medium containing NGF (+N) or anti-NGF antibody ( N). Sixteen hours later, whole cell extracts were prepared. (a) EMSA experi-
ments were performed using oligonucleotides containing either the wild type dp5 ATF site or mutant site, in which four nucleotides have been
changed (Figure 4a). Eight micrograms of +N or –N whole cell extract was used per binding reaction, as indicated. A control antibody (against
Bim) or c-Jun or ATF2 antibodies were added as shown. The binding reactions were separated on a 5% polyacrylamide, 0.25  TBE gel. Several
experiments were performed and a representative result is shown. Free probe, a non-speciﬁc complex (NS) and the AP-1 complexes are indicated. The
four point mutations inhibited the binding of AP-1 proteins to the dp5 ATF site. The c-Jun antibody caused a supershift (s s) whereas the ATF2
antibody partially reduced binding of the AP-1 complexes. (b) Eﬀect of phospho-c-Jun (Serine 63) and phospho-ATF2 (Threonine 71) antibodies on
the binding of AP-1 proteins to the dp5 ATF site. Only the top of the gel is shown. The positions of the AP-1 complexes and supershifted complexes
(s s) are indicated. (c) The amount of c-Jun phosphorylated at serine 63 bound to the dp5 ATF site increases after NGF withdrawal. Only the top of
the gel is shown. The positions of the AP-1 complexes and supershifted complexes (s s) are indicated.
Nucleic Acids Research,2009, Vol.37, No. 9 3053to the dp5 ATF site not only reduces the induction of dp5
expression following NGF withdrawal but also decreases
basal promoter activity. Finally, we investigated the eﬀect
of the MLK inhibitor CEP-11004 (at 400nM) on the
activity of the mutant construct (Figure 7c). CEP-11004
did not signiﬁcantly reduce the 3-fold increase in the activ-
ity of the reporter with mutated ATF site that occurs after
NGF withdrawal (Figure 7c). This is diﬀerent to the eﬀect
of CEP-11004 on the wild type dp5-LUC+ALL con-
struct (Figure 2d) and suggests that the 3-fold induction
observed in the absence of the ATF site is independent of
the MLK-JNK pathway.
Dominant negativec-Jun reduces theincrease indp5
reporter activity andthe increasein thelevel of
endogenous dp5 RNA after NGF withdrawal
Expression of a c-Jun dominant negative mutant
(Jun169) in sympathetic neurons protects the cells
against NGF withdrawal-induced death (7,14) and
reduces the increase in the level of the c-Jun and BimEL
proteins that normally occurs after the removal of NGF
(10,14). We therefore investigated the eﬀect of dominant
negative c-Jun on dp5 reporter activity and the endogen-
ous dp5 gene in sympathetic neurons.
First, using in vitro translated proteins we studied how
Jun169 binds to the dp5 ATF site in an EMSA experi-
ment (Figure 8a). Like c-Jun, Jun169 was unable to bind
to the dp5 ATF site on its own, whereas ATF2 homodi-
mers were able to do so (lanes 1–5, Figure 8a). When c-Jun
was mixed with ATF2, c-Jun/ATF2 heterodimers formed
a protein/DNA complex that ran just below the ATF2/
DNA complex (compare lanes 6 and 5). Jun169 also
formed heterodimers with ATF2 that could bind to the
Figure 7. Mutation of an ATF-binding site in the dp5 promoter reduces basal promoter activity and induction after NGF withdrawal. Sympathetic
neurons were microinjected with dp5-LUC+ALL or a reporter construct in which the ATF-binding site in the dp5 promoter had been mutated (dp5-
LUC+ALLmut) (both at 10ng/ml) as well as pRL-TK (5ng/ml). Cells were maintained in medium containing or lacking NGF for 20h, after which
time luciferase activity was measured. (a) Normalized ﬁreﬂy luciferase activity was calculated relative to the level +NGF microinjected with the wild-
type construct, which was set as 1. The mean of six independent experiments  SEM is shown. (b) The induction factor for the same series of
experiments was calculated for each reporter construct=(normalized ﬁreﬂy luciferase activity –NGF)/(normalized ﬁreﬂy luciferase activity +NGF).
(c) CEP-11004 does not reduce the activity of the reporter with mutated ATF site after NGF withdrawal. The reporter construct in which the ATF-
binding site in the dp5 promoter had been mutated (dp5-LUC+ALLmut) (10ng/ml) was microinjected into sympathetic neurons together with pRL-
TK (5ng/ml). Cells were maintained in medium containing or lacking NGF with either DMSO or 400 nM CEP-11004 as indicated for 20h, after
which time luciferase activity was measured. Normalized ﬁreﬂy luciferase activity was calculated relative to the level +NGF, which was set as 1. The
mean of six independent experiments   SEM is shown.
Figure 6. c-Jun and ATF2 bind to the dp5 ATF site in the chromatin
of neuronally diﬀerentiated PC12 cells. The PC6-3 subline of PC12
cells was treated with NGF at 100ng/ml for 7 days. The neuronally
diﬀerentiated cells were then refed with fresh diﬀerentiation medium
containing NGF (+N) or anti-NGF antibody ( N). After 16h, the
cells were cross-linked with 1% formaldehyde and chromatin immu-
noprecipitations were performed using (a) the c-Jun(H-79) or
ATF2(C-19) antibodies or a Bim antibody as a negative control or
(b) the phospho-c-Jun (serine 63) (KM-1) or Bim antibodies. As a
positive control, PCR was performed using primers that ﬂank the
jun1 and jun2 TREs in the c-jun promoter, which have previously
been shown to bind c-Jun and ATF2 in chromatin. Binding of c-Jun
and ATF2 to the dp5 promoter was detected by performing PCR
using primers that ﬂank the dp5 ATF site. The ChIP experiments
were performed several times and representative gel images are
shown. The positions of the c-jun and dp5 PCR products are indi-
cated. The equivalent of 1% of the +N and –N chromatin used for
each ChIP assay was also run on each gel (input lanes). As a neg-
ative control a PCR reaction without chromatin was performed
(H2O).
3054 Nucleic Acids Research, 2009, Vol. 37,No. 9dp5 ATF site (lane 7). However, when the m0 leucine
zipper mutation (31), which blocks binding to ATF2,
was present in Jun169 (169m0), the dominant negative
c-Jun/ATF2/DNA complex was no longer observed
(lane 8). Thus, Jun169 can only bind to the dp5 ATF
site as a heterodimer with ATF2. We then investigated the
eﬀect of dominant negative c-Jun on the dp5-LUC+ALL
reporter construct in a co-microinjection experiment
(Figure 8b). We injected an expression vector for
Jun169 or the empty vector pcDNA1 into sympathetic
Figure 8. Expression of dominant negative c-Jun reduces the induction of a dp5 reporter construct and the endogenous dp5 RNA after NGF
withdrawal. (a) c-Jun169 binds to the dp5 ATF site as a heterodimer with ATF2. An oligonucleotide containing the dp5 ATF site was incubated
with in vitro translated c-Jun, c-Jun169, 169m0, ATF2 or unprogrammed rabbit reticulocyte lysate (RRL) as indicated, and an EMSA experiment
was performed. Only the regions of the gel that contain the protein/DNA complexes and the unbound probe are shown, to make the ﬁgure more
compact. (b) Co-injection of an expression vector for dominant negative c-Jun (Jun169) reduces induction of a dp5 reporter construct after NGF
withdrawal. Sympathetic neurons were microinjected with dp5-LUC+ALL (20ng/ml), pRL-TK (10ng/ml) and pcDNA1 or pCDJun169 (100ng/ml).
Cells were maintained +NGF or –NGF for  20h and then luciferase activity was measured. Fireﬂy luciferase levels were normalized and luciferase
activity was calculated relative to the level +NGF, which was set as 1, for either pcDNA1 or pCDFLAG169. The mean of nine independent
experiments  SEM is shown. In the case of empty vector the increase in reporter gene activity after NGF withdrawal was signiﬁcant:  P<0.002,
Student’s t-test. For pCDJun169 the increase in reporter activity after NGF deprivation was not signiﬁcant:
#P>0.1, Student’s t-test. (c)
Sympathetic neurons infected with AdvJun169 or AdvlacZ express recombinant proteins of the predicted size. Sympathetic neurons were cultured
for 5 days in vitro and then infected with recombinant adenoviruses as indicated. After overnight infection, the cells were refed with fresh SCG
medium containing NGF. Forty eight hours later, protein extracts were prepared and immunoblots performed with antibodies to b-galactosidase,
a-tubulin (a loading control) and the FLAG epitope. The positions of protein molecular weight markers run on the same 12% gel are shown. (d)
RT–PCR analysis of dp5 and nfm mRNA levels in adenovirus-infected neurons expressing b-galactosidase or the Jun169 protein. Sympathetic
neurons were cultured for 5 days in vitro and then infected with the recombinant adenoviruses indicated. After overnight infection, the cells were
refed with fresh SCG medium containing NGF (+NGF) or anti-NGF antibody (-NGF). Sixteen hours later, RNA was isolated and semi-
quantitative RT–PCR performed with primers speciﬁc for dp5 or nfm. Thirty-ﬁve cycles of PCR were performed and the products were run on a
2.5% agarose gel. (e) AdvJun169 reduces the increase in dp5 RNA levels after NGF withdrawal. RT–PCR analysis of dp5 and nfm mRNA levels in
adenovirus-infected neurons was carried out as described in (d). dp5 mRNA levels were normalized to nfm RNA levels to control for any diﬀerences
in the amount of cDNA used for each RT–PCR reaction. The induction factor (the normalized dp5 RNA level –NGF/+NGF) was then calculated
for each virus. The average of ﬁve experiments   SEM is shown.
Nucleic Acids Research,2009, Vol.37, No. 9 3055neurons together with dp5-LUC+ALL and luciferase
activity was measured 20–24h after NGF withdrawal.
Expression of Jun169 reduced the induction of the
dp5-LUC+ALL reporter construct after NGF with-
drawal from 2.275 0.322-fold with pcDNA1 (P<0.002
when –NGF is compared to +NGF) to 1.492 0.29-fold,
which was not a signiﬁcant induction (P>0.1) when
–NGF was compared to +NGF. This result suggests
that AP-1 activity is required for normal induction of
the dp5 reporter construct following NGF deprivation.
To determine whether AP-1 activity contributes to the
induction of the endogenous dp5 mRNA after NGF with-
drawal we used a recombinant adenovirus that expresses
dominant negative c-Jun (AdvJun169) (14) and, as a
control, an adenovirus that expresses E. coli b-galactosi-
dase (AdvlacZ). In an immunoblotting experiment with
protein extracts prepared from uninfected sympathetic
neurons and adenovirus-infected cells we conﬁrmed that
AdvJun169 and AdvlacZ express recombinant proteins
with the predicted molecular weights (Figure 8c). We then
tested the eﬀect of the two adenoviruses on the level of dp5
mRNA (Figure 8d and e). Sympathetic neurons were cul-
tured for 5 days in vitro and then infected overnight with
the Jun169 or b-galactosidase adenovirus at MOIs that
led to expression of the recombinant proteins in  50% of
the infected neurons (14). After infection, the cells were
refed with +NGF medium and  24h later were rinsed
and maintained in medium containing NGF or a neutra-
lising anti-NGF antibody for 16h. RNA was then isolated
and semi-quantitative RT–PCR was performed to mea-
sure dp5 and nfm mRNA levels (Figure 8d). Expression
of Jun169 did not alter the level of the nfm mRNA
(Figure 8d). In the case of sympathetic neurons infected
with AdvlacZ, the dp5 mRNA increased 6.02-fold after
NGF withdrawal, but in cells infected with AdvJun169
the induction was reduced to 2.34-fold (Figure 8e). This
result suggests that in sympathetic neurons AP-1 activity
contributes to the induction of the endogenous dp5
mRNA following NGF withdrawal.
Microinjection of an antibody against c-Jun, but not
Jun B or Jun D antibodies or control IgG, has been
shown to inhibit the NGF withdrawal-induced death of
sympathetic neurons (6). To study the individual contri-
butions of c-Jun and ATF2 to the activation of dp5-
LUC+ALL after NGF withdrawal we therefore carried
out an antibody co-injection experiment (Figure 9a).
The dp5 reporter construct was injected into the nuclei
of sympathetic neurons together with control rabbit
immunoglobulin or the c-Jun or ATF2 antibodies that
had been used for chromatin immunoprecipitation. With
the control antibody, dp5-LUC+ALL was activated
5.3-fold on average after NGF withdrawal whereas
co-injection of the c-Jun or ATF2 antibodies reduced
the induction factor to 2.83- or 2.47-fold, respectively.
At the concentration tested, neither of these antibodies
aﬀected basal promoter activity in the presence of NGF.
Importantly, the c-Jun and ATF2 antibodies did not aﬀect
the activation of pCRE-Luc, a CREB reporter construct,
when CPTcAMP, a membrane permeable cAMP analo-
gue, was added to the cells to activate protein kinase A
and CREB (Figure 9b).
Finally, we investigated the eﬀect of co-injecting an
expression vector for c-Jun (ala) with dp5-LUC+ALL
(Figure 9c). c-Jun (ala) is a mutant of c-Jun in which all
of the potential JNK phosphorylation sites (serines 63 and
73 and threonines 91 and 93) have been mutated to ala-
nine (28). Expression of c-Jun (ala) signiﬁcantly reduced
the induction factor after NGF withdrawal from
5.47 1.35-fold with pcDNA3 to 2.87 0.72-fold. These
results suggest that following NGF withdrawal both c-Jun
and ATF2 contribute to the activation of the dp5 pro-
moter in dp5-LUC+ALL and that the JNK phosphoryla-
tion sites in c-Jun are necessary for full induction of the
dp5 promoter.
DISCUSSION
In sympathetic neurons the level of the dp5 RNA increases
substantially after NGF withdrawal, and this depends on
the MLK-JNK pathway (21,22). Here, we have investi-
gated the mechanism by which this protein kinase cascade
regulates dp5 expression, and propose a model by which
this occurs (Figure 10). To identify regulatory sequences in
the dp5 gene we made reporter constructs containing dif-
ferent regions of dp5 linked to luciferase. In microinjection
experiments with sympathetic neurons, we found that con-
structs containing 1kb of promoter sequence alone or with
a short sequence from the intron and/or the whole 30 UTR
were all activated following NGF deprivation. The highest
level of induction was observed when all three regions
were present together in the dp5-LUC+ALL construct.
The increase in dp5 RNA level after NGF deprivation
was reduced by treating cells with the MLK inhibitor
CEP-11004, conﬁrming the results of Harris and
Johnson (22), who used the related compound CEP-
1347. Not only did CEP-11004 decrease dp5 expression
after NGF withdrawal, but it also reduced the induction
of a dp5 luciferase reporter plasmid, suggesting that this
construct behaves in a similar manner to the endogenous
dp5 gene. We also co-injected sympathetic neurons with
the dp5 reporter construct and an expression vector for the
JIP-1 JBD. This JNK inhibitor protein strongly reduced
the induction of dp5-LUC+ALL after NGF withdrawal,
suggesting that the activation of dp5 transcription by
MLKs is mediated by JNKs.
We identiﬁed a conserved ATF-binding site in the dp5
promoter that is similar to the jun2 TRE in the c-jun
promoter. We showed that this site is able to bind c-Jun
and ATF2 in vitro and in chromatin, and to study its role
in the dp5 promoter we mutated it in a dp5 reporter con-
struct so as to abolish AP-1 binding. This reduced the
induction of the reporter plasmid after NGF withdrawal
and signiﬁcantly reduced basal promoter activity suggest-
ing that this site is an important dp5 promoter element.
In sympathetic neurons cultured in the presence of NGF,
the dp5 ATF site may contribute to basal promoter activ-
ity by binding c-Jun/ATF2 heterodimers. After NGF
withdrawal, the level of active, phosphorylated c-Jun pres-
ent in the nucleus increases (9,10) and this would lead
to an increase in the activity of c-Jun/ATF2 heterodimers,
3056 Nucleic Acids Research, 2009, Vol. 37,No. 9which could contribute to the induction of dp5
transcription.
To further study the role of AP-1 in the induction of
dp5 transcription we tested the eﬀect of overexpressing
a c-Jun dominant negative mutant, Jun169, that can
form heterodimers with ATF2 and bind to ATF sites,
but which lacks the ﬁrst 168 amino acids of c-Jun
including the N-terminal transactivation domain, the
JNK docking site and the JNK phosphorylation sites.
We found that Jun169 reduced the induction of a dp5
reporter construct and also decreased endogenous dp5
RNA and protein levels after NGF withdrawal suggest-
ing that dp5 is an AP-1 target gene and that the
MLK-JNK pathway activates dp5 transcription via
the ATF site (Figure 10). In addition, co-microinjection
of either a c-Jun or ATF2 antibody together with dp5-
LUC+ALL reduced the activation of the reporter
construct after NGF withdrawal suggesting that both
Figure 9. Co-injection of antibodies speciﬁc for c-Jun or ATF2 reduces the induction of a dp5 reporter gene after NGF withdrawal. (a) Sympathetic
neurons were cultured for 6 days in vitro and then microinjected with dp5-LUC+ALL (20ng/ml), pRL-TK (10ng/ml) and the c-Jun (H-79) or ATF2
(C-19) antibodies or rabbit immunoglobulin as a control (each at 1mg/ml) as indicated. After injection, the cells were maintained in medium
containing NGF (+) or anti-NGF antibody ( ) for 20h before luciferase activity was measured. For each experiment the level of normalized
luciferase activity (ﬁreﬂy output/Renilla output) obtained for neurons injected with dp5-LUC+ALL + control IgG and maintained in medium
containing NGF was set as 1 and other values were calculated relative to this (relative luciferase activity). The mean   SEM for ﬁve independent
experiments is shown, and induction factors ( NGF/+NGF) are given above the graph. Student’s t-test was used to determine whether inductions
were signiﬁcant:  P<0.05;
#P<0.02;
+P>0.1. (b) Sympathetic neurons were microinjected with pLuc-MCS or pCRE-Luc at 20ng/ml, pRL-TK
(10ng/ml) and the indicated antibodies (1mg/ml). After injection the cells were treated with 500mM CPTcAMP to activate PKA and CREB.
Normalized luciferase activity was calculated relative to pLuc-MCS, which lacks CRE sites and which was set as 0.1. The mean   SEM for four
independent experiments is shown. (c) Expression of c-Jun (ala) signiﬁcantly reduces the induction of the dp5 promoter after NGF withdrawal. Dp5-
LUC+ALL (20ng/ml), pRL-TK (10ng/ml) and pcDNA3 or CMV c-Jun (ala) (100ng/ml) were microinjected into sympathetic neurons as indicated.
The cells were then maintained in medium containing NGF (+) or anti-NGF antibody ( ) for 20h before luciferase activity was measured. Fireﬂy
luciferase levels were normalized and luciferase activity was calculated relative to the level +NGF, which was set as 1, for either pcDNA3 or CMV
c-Jun (ala). The mean of seven independent experiments   SEM is shown.  P<0.05 when Dp5-LUC+ALL + CMV c-Jun (ala) –NGF is compared
to Dp5-LUC+ALL + pcDNA3 –NGF in Student’s t-test.
Nucleic Acids Research,2009, Vol.37, No. 9 3057c-Jun and ATF2 contribute to the activation of the dp5
promoter (Figure 9).
The expression of Dp5 increases in a range of neural cell
types following injury, stress or survival factor withdra-
wal, and several studies suggest that JNK may regulate
Dp5 levels in response to a variety of apoptotic stimuli.
dp5 mRNA levels increase in cultured rat cortical neurons
following treatment with b-amyloid peptide (41) and
this increase can be blocked by CEP-1347 (38). Work
carried out with oligodendrocytes also suggests that the
b-amyloid-induced upregulation of dp5 and cell death
is mediated by the JNK pathway since treatment with
b-amyloid peptide increased JNK phosphorylation and
AP-1 DNA-binding activity (42). Recently, Ma et al.
(43) reported that expression of shRNAs against dp5 can
partially protect rat cerebellar granule neurons (CGNs)
against apoptosis induced by KCl deprivation. In addi-
tion, these authors also demonstrated that the ATF
site in the dp5 promoter is bound by c-Jun in CGNs
and important for dp5 promoter activation following sur-
vival signal withdrawal, in agreement with the results
reported here.
Since the discovery that NGF withdrawal-induced
death requires de novo gene expression (3) our understand-
ing of the events that occur in sympathetic neurons fol-
lowing NGF deprivation has greatly increased and a
number of the genes involved in this process have been
identiﬁed. The MLK-JNK-c-Jun pathway is one of the
important proapoptotic signalling pathways activated
after NGF withdrawal (Figure 10). Activation of the
MLK-JNK pathway leads to the phosphorylation of
c-Jun bound to the c-jun promoter, which increases the
rate of transcription of the c-jun gene and increases the
level of c-Jun, an important JNK substrate which is
required for the normal NGF withdrawal-induced death
of sympathetic neurons (15). c-Jun contributes to the
increased expression of the BH3-only proteins BimEL
(14,24) and Dp5 (43, and this study), which together
with Puma, bind to antiapoptotic Bcl-2 family members
and promote mitochondrial outer membrane permeabili-
sation. In addition, JNKs can regulate BimEL at the post-
translational level by phosphorylating serine 65 and
potentiating its proapoptotic activity (44). Therefore
in the future it will be important to identify other tran-
scriptional targets of the JNK pathway as well as further
investigate the post-translational eﬀects of JNK
phosphorylation.
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